Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AZN 
AstraZeneca PLC ADR (AZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: AZN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $87.37
1 Year Target Price $87.37
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.25% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 240.47B USD | Price to earnings Ratio 29.27 | 1Y Target Price 87.37 |
Price to earnings Ratio 29.27 | 1Y Target Price 87.37 | ||
Volume (30-day avg) 12 | Beta 0.17 | 52 Weeks Range 60.83 - 82.41 | Updated Date 09/17/2025 |
52 Weeks Range 60.83 - 82.41 | Updated Date 09/17/2025 | ||
Dividends yield (FY) 2.02% | Basic EPS (TTM) 2.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.68% | Operating Margin (TTM) 24.12% |
Management Effectiveness
Return on Assets (TTM) 8.28% | Return on Equity (TTM) 19.67% |
Valuation
Trailing PE 29.27 | Forward PE 15.06 | Enterprise Value 264973324501 | Price to Sales(TTM) 4.26 |
Enterprise Value 264973324501 | Price to Sales(TTM) 4.26 | ||
Enterprise Value to Revenue 4.69 | Enterprise Value to EBITDA 15.74 | Shares Outstanding 3100499968 | Shares Floating 1542932000 |
Shares Outstanding 3100499968 | Shares Floating 1542932000 | ||
Percent Insiders - | Percent Institutions 16.73 |
Upturn AI SWOT
AstraZeneca PLC ADR
Company Overview
History and Background
AstraZeneca PLC ADR was formed in 1999 through the merger of Swedish Astra AB and British Zeneca Group PLC. It has grown through internal research and development, as well as strategic acquisitions, to become a major global pharmaceutical company.
Core Business Areas
- Oncology: Focuses on developing and commercializing cancer therapies, including targeted treatments, immunotherapies, and cell therapies.
- Cardiovascular, Renal & Metabolism (CVRM): Develops medicines for heart failure, chronic kidney disease, diabetes, and related conditions.
- Respiratory & Immunology: Focuses on treating asthma, COPD, and other respiratory and immunological diseases.
- Rare Diseases: Dedicated to developing and delivering innovative therapies to treat people with rare diseases
- Vaccines and Immune Therapies: Vaccines to help with global health concerns.
Leadership and Structure
AstraZeneca is led by a Chief Executive Officer (CEO) and a Board of Directors. The organizational structure includes various functional and therapeutic area divisions.
Top Products and Market Share
Key Offerings
- Product Name 1: Tagrisso (Osimertinib) - A targeted therapy for EGFR-mutated non-small cell lung cancer. Competitors include Roche's Tarceva, and Boehringer Ingelheim's Giotrif. Market share varies by region and line of treatment, but Tagrisso holds a significant share in first-line treatment of EGFR-mutated NSCLC.
- Revenue: 5454000000
- Product Name 2: Farxiga/Forxiga (Dapagliflozin) - An SGLT2 inhibitor for type 2 diabetes and heart failure. Competitors include Jardiance (Eli Lilly/Boehringer Ingelheim) and Invokana (Janssen). Farxiga holds a strong position in the SGLT2 inhibitor market, particularly in heart failure.
- Revenue: 5965000000
- Product Name 3: Imfinzi (Durvalumab) - A PD-L1 inhibitor used in various cancers, including lung cancer and bladder cancer. Competitors include Keytruda (Merck) and Opdivo (Bristol Myers Squibb). Imfinzi has gained significant market share in unresectable Stage III non-small cell lung cancer following chemoradiation.
- Revenue: 4241000000
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory oversight, and increasing competition. There is growing demand for innovative therapies, especially in oncology and rare diseases.
Positioning
AstraZeneca is a leading global pharmaceutical company with a strong focus on innovative medicines. It has a diverse portfolio and a significant presence in key therapeutic areas. Their advantage lies in novel therapies such as personalized medicine.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1.4 trillion, expected to keep growing as the worldwide population ages. AstraZeneca is positioned to capture a significant share of this TAM.
Upturn SWOT Analysis
Strengths
- Strong pipeline of new drugs
- Significant presence in key therapeutic areas
- Established global infrastructure
- Strong R&D capabilities
- Diversified portfolio of products
Weaknesses
- Reliance on key products facing patent expiration
- High R&D costs
- Exposure to generic competition
- Dependence on regulatory approvals
- Potential for clinical trial failures
Opportunities
- Expanding into emerging markets
- Acquiring or partnering with biotech companies
- Developing personalized medicine solutions
- Leveraging digital health technologies
- Addressing unmet medical needs
Threats
- Increasing regulatory scrutiny
- Pricing pressures from governments and payers
- Generic competition
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
- BMY
Competitive Landscape
AstraZeneca faces intense competition from other major pharmaceutical companies. It competes based on innovation, product portfolio, and market access.
Major Acquisitions
Alexion Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 39000
- Strategic Rationale: Expanded AstraZeneca's presence in rare diseases and strengthened its immunology portfolio.
Growth Trajectory and Initiatives
Historical Growth: AstraZeneca has experienced growth driven by new product launches and acquisitions.
Future Projections: Analyst estimates project continued revenue growth driven by key products in oncology and other therapeutic areas.
Recent Initiatives: Recent initiatives include acquisitions of other companies, strategic collaborations, and expansion into new markets.
Summary
AstraZeneca is a strong player in the pharmaceutical industry, driven by innovative medicines and strategic acquisitions. Its oncology and CVRM portfolios are performing well. However, it needs to carefully manage generic competition and regulatory pressures to maintain its growth trajectory and it should look to improve its EPS. Overall, it is a well diversified company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AstraZeneca PLC ADR Annual Reports
- SEC Filings
- Analyst Reports
- Company Investor Relations
- Yahoo Finance
- MarketWatch
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AstraZeneca PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-05-12 | CEO & Executive Director Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 94300 | Website https://www.astrazeneca.com |
Full time employees 94300 | Website https://www.astrazeneca.com | ||
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.